Adage Capital Management, L.P., along with managing members Robert Atchinson and Phillip Gross, filed a Schedule 13G with the SEC on November 12, 2026, disclosing a 5.81% beneficial ownership position in First Tracks Biotherapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: 2,077,179 shares of Common Stock, $0.001 par value per share, reported by each of the three reporting persons.
  • Percent of class: 5.81%, calculated based on 35,730,843 shares outstanding as of August 7, 2026.
  • Voting and dispositive power: All 2,077,179 shares are held with shared voting and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Triggering event date: September 30, 2026, is cited as the date of the event requiring this filing.
  • Shares held through: Adage Capital Partners, L.P., with Adage Capital Management, L.P. acting as investment manager, according to the filing.
  • Business address: All reporting persons list 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116 as their business address.

Adage Capital Management's Ownership Structure in First Tracks Biotherapeutics

According to the filing, Adage Capital Management, L.P. ("ACM"), a Delaware limited partnership, serves as the investment manager of Adage Capital Partners, L.P. ("ACP"), which directly holds the reported shares of common stock in First Tracks Biotherapeutics, Inc. The issuer's principal executive offices are located at 10770 Wateridge Circle, Suite 210, San Diego, CA, 92121, and its common stock carries a CUSIP number of 337185102. The filing does not identify a specific exchange or ticker symbol for the issuer's securities.

Robert Atchinson and Phillip Gross are each identified as reporting persons in their capacity as managing members of several affiliated entities within the Adage Capital structure. The filing states that Atchinson is a managing member of Adage Capital Advisors, L.L.C. and Adage Capital Partners GP, L.L.C., the general partner of ACP, and also a managing member of Adage Capital Partners, L.L.C., the general partner of ACM. Gross holds the same set of roles, according to the filing. Both individuals are citizens of the United States.

The 5.81% ownership figure is based on 35,730,843 shares of common stock outstanding as of August 7, 2026, as reported in First Tracks Biotherapeutics' Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, according to the Schedule 13G. The filing includes a certification stating that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross filed a Schedule 13G reporting shared beneficial ownership of 2,077,179 shares, or 5.81%, of First Tracks Biotherapeutics, Inc. common stock, with the triggering event dated September 30, 2026.